Date: March 23, 2020
To: Calgary Zone Clinicians
From: Clinical Biochemistry Section, South Sector, Alberta Precision Laboratories (APL)
Re: Transfer of Tests from MitogenDx to APL in Calgary

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:
• Effective April 6 2020, the following tests currently performed at MitogenDx will be performed by APL in Calgary:
  o When ordered in SCM or a manual requisition, the test will be cancelled by the laboratory and the appropriate APL test will be performed.
  o Samples will be stored up to 6 months from collection date if further testing is required

<table>
<thead>
<tr>
<th>MitogenDx Test</th>
<th>Corresponding test performed by APL Calgary:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-cellular antibodies (International Consensus on ANA Patterns; ICAP style reporting)</td>
<td>Anti-nuclear antibodies (ICAP style reporting)</td>
</tr>
<tr>
<td>Anti-dsDNA (Chemiluminescence immunoassay; CIA; Inova)</td>
<td>Anti-dsDNA (Addressable laser bead immunoassay; ALBIA; Bio-Rad)</td>
</tr>
<tr>
<td>Systemic lupus profile (Line immunoblot; Euroimmun)</td>
<td>Extractable nuclear antigen antibodies (ENA; ALBIA; Bio-Rad)</td>
</tr>
<tr>
<td>dsDNA, chromatin, Ribo-P, Ro52/TRIM21, SSA/Ro60, SSB/La, Sm, U1RNP, PCNA, Ku</td>
<td>dsDNA, chromatin, Ribo-P, Ro52/TRIM21, SSA/Ro60, SSB/La, CENPB, Sm, SmRNP, RNP68, RNPA, Scl-70, Jo-1</td>
</tr>
<tr>
<td>Sjögren’s syndrome profile (Line immunoblot; Euroimmun) SSA/Ro60, SSB/La, Ro52/TRIM21</td>
<td>ENA (ALBIA; Bio-Rad) including SSA/Ro60, SSB/La, Ro52/TRIM21</td>
</tr>
<tr>
<td>Arthritis panel (Anti-HCP1/2; -VCP1/2; ALBIA, TheraDiag)</td>
<td>Cyclic citrullinated peptide antibodies (CCP2; CIA; Abbott)</td>
</tr>
<tr>
<td>Anti-neutrophil cytoplasmic antibody (ANCA; anti-MPO, -PR3; CIA, Inova)</td>
<td>ANCA (indirect immunofluorescence microscopy; Euroimmun; anti-MPO, -PR3; ALBIA, Bio-Rad)</td>
</tr>
<tr>
<td>Anti-phospholipid syndrome (anti-domain 1 beta-2 glycoprotein, PS/PT IgG/IgM; CIA; Inova)</td>
<td>Anti-beta-2-glycoprotein I IgG Anti-cardiolipin IgG (ALBIA; Bio-Rad)</td>
</tr>
</tbody>
</table>

Importance/Impact:
• This change will increase the efficiency of laboratory collections and reporting, and decrease duplication of tests.

Background:
• As APL is mandated to provide publically funded laboratory testing in Alberta, referred out testing is regularly reviewed.
• Appropriate specific autoimmune tests will now be performed in collaboration with MitogenDx and Dr. Marvin Fritzler.
• This is the first phase of implementation and will affect other zones in the future.
Action Required:

- Contact Dr. Alex Chin at 403-770-3222 or alex.chin@albertaprecisionlabs.ca if further consultation is required.

Inquiries and feedback may be directed to:

- Alex C. Chin, PhD, DABCC, FAACC, FCACB Clinical Biochemist, South Sector
- Marvin Fritzler, MD, PhD, Director, MitogenDx (403-220-3533, fritzler@ucalgary.ca)
- Hossein Sadrzadeh, PhD, DABCC, FAACC, Clinical Section Chief, Clinical Biochemistry, South Sector, 403-770-3759, hossein.sadrzadeh@albertaprecisionlabs.ca

This memorandum has been reviewed and approved by:

Hossein Sadrzadeh, PhD, DABCC, FAACC, Clinical Section Chief, Clinical Biochemistry, South Sector
Leland Baskin, MD, FCAP, FAACC, Associate Medical Director, South Sector
Carolyn O’Hara, MD FRCPC, Interim Chief Medical Laboratory Officer